Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Trimi vs Contour Health

Two GLP-1 desks, one scoreboard. We put Trimi and Contour Health head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 2 · Grade B+

Trimi

Visit Trimi Full brief →
vs
No. 155 · Grade C

Contour Health

Visit Contour Health Full brief →

The verdict

Trimi takes this head-to-head.

Trimi scores 89 to 68 on our six-factor Brief Score — A clean, all-in membership desk that publishes one price on both molecules nationwide and hasn't played the teaser-rate game.

That doesn't make Contour Health a bad call — it's best for readers who want pay-per-vial compounded semaglutide or tirzepatide with no long-term subscription commitment. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
90
48
Supply Reliability
89
81
Transparency
91
72
Access Breadth
89
50
Clinical Oversight
88
85
Track Record
84
80
TrimiBrief Score 89 · 68Contour Health

Price, coverage & the tracker

TrimiContour Health
Brief Score89/100 (B+)68/100 (C)
Semaglutide$196/moFrom $160/mo (starting dose, compounded)
Tirzepatide$296/moFrom $300/mo (starting dose, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

Trimi: Membership rate held flat this cycle — both molecules disclosed up front, no first-month teaser.

Contour Health: New to the tracker on 1 August 2026. The published line reads From $160/mo (starting dose, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.